Be among the first to explore the upcoming enhancements to the MyRisk® Hereditary Cancer Test. This session will unveil expanded gene coverage, including 15 newly added guideline-recommended genes and 36 evidence-based intronic variants. Our clinical experts will discuss the associated cancer risks and how these updates empower healthcare providers to deliver more personalized risk assessments and confidently guide patient management.

  • Discuss the enhancements for the MyRisk Hereditary Cancer Test
  • Take a deeper look at select genes being added the the MyRisk Hereditary Cancer Test
  • Review how variants are classified at Myriad

Hear from our Speakers

Kallie Woods MS, CGC

Kallie Woods, MS, CGC, is a board-certified genetic counselor and Oncology Medical Science Liaison at Myriad Genetics, where she has worked for the past six years. She partners with clinical providers across middle America to deliver education and support around hereditary cancer risk assessment and tumor molecular profiling. Kallie is deeply passionate about expanding access to genetic and genomic testing to advance equitable, high-quality healthcare. Prior to joining Myriad, she spent over four years as a clinical cancer genetic counselor in Kansas City, specializing in hereditary cancer syndromes.